Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis
Open Access
Abstract
Background: Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma characterized by a poor prognosis due to high relapse rates and a lack of standardized treatment. This study aimed to evaluate the impact of induction/consolidation therapy on long-term survival and to provide extended follow-up data. Methods: In this retrospective analysis, 140 immunocompetent patients with diffuse large B-cell PCNSL (DLBCL-PCNSL) treated at two centers between 2014 and 2024 were enrolled. Treatment efficacy was assessed based on baseline characteristics, therapeutic regimens, and treatment response. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were identified using multivariate Cox proportional hazards regression models. Results: With a median follow-up of 5.3 years (range: 0.1–11.0 years), the 2- and 5-year PFS rates were 50.4% (95% CI: 42.1–60.2) and 34.1% (95% CI: 25.5–45.0), respectively, while the corresponding OS rates were 85.3% (95% CI: 79.4–91.6) and 60.8% (95% CI: 52.0–71.1). No survival plateau was observed. Among patients, 94% received methotrexate-based induction therapy: 94 received rituximab–methotrexate–temozolomide (R-MT) and 17 received MT alone, with 2-year PFS rates of 57.7% and 39.7%, respectively. Overall, 75% of patients achieved remission (CR/CRu/PR) after induction, and among these, 55% underwent consolidation therapy, predominantly autologous stem cell transplantation (ASCT, 90%) or whole-brain radiotherapy (10%). Patients receiving ASCT exhibited superior survival outcomes compared to those who did not. Conclusions: R-MT induction combined with ASCT consolidation is associated with improved survival in PCNSL, although relapse risk remains substantial. Outcomes remain poor in refractory subgroups, highlighting the need for novel therapeutic strategies.Keywords
Funding Information
- Beijing Research Ward Excellence Program (BRWEP2024032150207)
- Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital
- Capital’s Funds for Health Improvement and Research (2022-1-2152)
- Capital’s Funds for Health Improvement and Research (2024-1-2151)
- National Natural Science Foundation of China (82270195)
- Beijing Natural Science Foundation (L244063)
- Beijing Natural Science Foundation (L244025)
This publication has 30 references indexed in Scilit:
- Real-world analysis of primary central nervous system diffuse large B-cell lymphomaCritical Reviews in Oncology/Hematology, 2025
- CAR T‐cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real‐life results of the LOC networkAmerican Journal of Hematology, 2024
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialLeukemia, 2022
- Nanomedicine for brain cancerAdvanced Drug Delivery Reviews, 2022
- Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysisHematological Oncology, 2019
- High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from ChinaCancer Medicine, 2019
- Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyThe Lancet Oncology, 2019
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialThe Lancet Haematology, 2016
- Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-OncologyThe Lancet Oncology, 2015
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialThe Lancet, 2009